Mangoceuticals Statistics
Total Valuation
Mangoceuticals has a market cap or net worth of $20.80 million. The enterprise value is $21.28 million.
Important Dates
The next estimated earnings date is Friday, November 14, 2025, after market close.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Mangoceuticals has 11.25 million shares outstanding. The number of shares has increased by 240.49% in one year.
| Current Share Class | 11.25M |
| Shares Outstanding | 11.25M |
| Shares Change (YoY) | +240.49% |
| Shares Change (QoQ) | +117.36% |
| Owned by Insiders (%) | 25.92% |
| Owned by Institutions (%) | 2.60% |
| Float | 7.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.75 |
| Forward PS | n/a |
| PB Ratio | 1.00 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 41.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07, with a Debt / Equity ratio of 0.03.
| Current Ratio | 0.07 |
| Quick Ratio | 0.06 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -85.90% and return on invested capital (ROIC) is -45.91%.
| Return on Equity (ROE) | -85.90% |
| Return on Assets (ROA) | -43.25% |
| Return on Invested Capital (ROIC) | -45.91% |
| Return on Capital Employed (ROCE) | -64.88% |
| Revenue Per Employee | $172,010 |
| Profits Per Employee | -$5.03M |
| Employee Count | 3 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.81% in the last 52 weeks. The beta is 2.40, so Mangoceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 2.40 |
| 52-Week Price Change | -25.81% |
| 50-Day Moving Average | 2.25 |
| 200-Day Moving Average | 2.39 |
| Relative Strength Index (RSI) | 38.96 |
| Average Volume (20 Days) | 284,362 |
Short Selling Information
The latest short interest is 91,694, so 0.82% of the outstanding shares have been sold short.
| Short Interest | 91,694 |
| Short Previous Month | 199,171 |
| Short % of Shares Out | 0.82% |
| Short % of Float | 1.25% |
| Short Ratio (days to cover) | 0.42 |
Income Statement
In the last 12 months, Mangoceuticals had revenue of $516,030 and -$15.08 million in losses. Loss per share was -$3.14.
| Revenue | 516,030 |
| Gross Profit | 314,786 |
| Operating Income | -12.48M |
| Pretax Income | -14.20M |
| Net Income | -15.08M |
| EBITDA | -10.54M |
| EBIT | -12.48M |
| Loss Per Share | -$3.14 |
Full Income Statement Balance Sheet
The company has $101,019 in cash and $630,117 in debt, giving a net cash position of -$529,098 or -$0.05 per share.
| Cash & Cash Equivalents | 101,019 |
| Total Debt | 630,117 |
| Net Cash | -529,098 |
| Net Cash Per Share | -$0.05 |
| Equity (Book Value) | 19.24M |
| Book Value Per Share | 1.81 |
| Working Capital | -1.48M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -5.83M |
| Capital Expenditures | n/a |
| Free Cash Flow | -5.83M |
| FCF Per Share | -$0.52 |
Full Cash Flow Statement Margins
| Gross Margin | 61.00% |
| Operating Margin | -2,419.08% |
| Pretax Margin | -2,752.48% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Mangoceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -240.49% |
| Shareholder Yield | -240.49% |
| Earnings Yield | -72.66% |
| FCF Yield | -28.08% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 16, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | Oct 16, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
Mangoceuticals has an Altman Z-Score of 0.34 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.34 |
| Piotroski F-Score | 2 |